These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26894929)

  • 1. Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth.
    Calarge CA; Murry DJ; Ziegler EE; Arnold LE
    J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):471-7. PubMed ID: 26894929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron homeostasis during risperidone treatment in children and adolescents.
    Calarge CA; Ziegler EE; Del Castillo N; Aman M; McDougle CJ; Scahill L; McCracken JT; Arnold LE
    J Clin Psychiatry; 2015 Nov; 76(11):1500-5. PubMed ID: 26301448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron deficiency in pediatric patients in long-term risperidone treatment.
    Calarge CA; Ziegler EE
    J Child Adolesc Psychopharmacol; 2013 Mar; 23(2):101-9. PubMed ID: 23480322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
    Haas M; Karcher K; Pandina GJ
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder.
    Calarge C; Farmer C; DiSilvestro R; Arnold LE
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):495-502. PubMed ID: 21186968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study.
    Calarge CA; Mills JA; Ziegler EE; Schlechte JA
    J Child Adolesc Psychopharmacol; 2018 Mar; 28(2):145-150. PubMed ID: 29112461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case series of eight aggressive young children treated with risperidone.
    Cesena M; Gonzalez-Heydrich J; Szigethy E; Kohlenberg TM; DeMaso DR
    J Child Adolesc Psychopharmacol; 2002; 12(4):337-45. PubMed ID: 12625994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron status in toddlerhood predicts sensitivity to psychostimulants in children.
    Turner CA; Xie D; Zimmerman BM; Calarge CA
    J Atten Disord; 2012 May; 16(4):295-303. PubMed ID: 20978274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
    Roke Y; Buitelaar JK; Boot AM; Tenback D; van Harten PN
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):432-9. PubMed ID: 23234586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron deficiency in children with attention-deficit/hyperactivity disorder.
    Konofal E; Lecendreux M; Arnulf I; Mouren MC
    Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1113-5. PubMed ID: 15583094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum ferritin in children with attention-deficit hyperactivity disorder.
    Millichap JG; Yee MM; Davidson SI
    Pediatr Neurol; 2006 Mar; 34(3):200-3. PubMed ID: 16504789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.
    Gagliano A; Germanò E; Pustorino G; Impallomeni C; D'Arrigo C; Calamoneri F; Spina E
    J Child Adolesc Psychopharmacol; 2004; 14(1):39-47. PubMed ID: 15142390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron deficiency in children with attention deficit hyperactivity disorder.
    Lahat E; Heyman E; Livne A; Goldman M; Berkovitch M; Zachor D
    Isr Med Assoc J; 2011 Sep; 13(9):530-3. PubMed ID: 21991711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron Deficiency Parameters in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Percinel I; Yazici KU; Ustundag B
    Child Psychiatry Hum Dev; 2016 Apr; 47(2):259-69. PubMed ID: 26092605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.
    Calarge CA; Zimmerman B; Xie D; Kuperman S; Schlechte JA
    J Clin Psychiatry; 2010 Mar; 71(3):338-47. PubMed ID: 20331935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced extrapyramidal reactions.
    Teoh L; Allen H; Kowalenko N
    J Paediatr Child Health; 2002 Feb; 38(1):95-7. PubMed ID: 11869410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the Taq1A variant in the dopamine Dâ‚‚ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
    Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
    Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.